Longitudinal study on Parkinson's disease in Luxembourg
Biomaterial Collection for Neurodegenerative Disease Research (ND Collection)
Luxembourg Institute of Health · NCT05266872
This study is tracking over 1,600 people with Parkinson's disease and healthy individuals in Luxembourg to better understand how the disease progresses and what factors might influence it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1800 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Luxembourg Institute of Health (other gov) |
| Locations | 2 sites (Luxembourg and 1 other locations) |
| Trial ID | NCT05266872 on ClinicalTrials.gov |
What this trial studies
The Luxembourg Parkinson's Study is an ongoing observational study that collects extensive clinical, molecular, genetic, and digital data from over 1,600 participants with Parkinson's disease and healthy controls. Participants are followed annually, with healthy controls assessed every four years, allowing for a comprehensive understanding of the disease's progression and risk factors. The study aims to create a deeply phenotyped cohort to support clinical and fundamental research on Parkinson's disease, utilizing an open-source digital platform harmonized with other international studies. This initiative includes rigorous biosampling to ensure high-quality data for future analyses.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with typical or atypical Parkinson's disease, aged 18 and older, who can provide informed consent.
Not a fit: Patients with active cancer, pregnant women, or those under 18 years of age will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and improved treatment strategies for Parkinson's disease.
How similar studies have performed: Other studies utilizing longitudinal cohort approaches in Parkinson's disease have shown promise, indicating that this methodology is both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects with neurodegenerative disease or having Parkinson's disease (typical PD or atypical parkinsonism) * Subjects of all genders with a full capacity of consent * Subjects with a limited consent capacity if the legal guardian/authorised representative is in agreement * Subjects of at least 18 years of age at the time of inclusion Exclusion Criteria: * Refusal to sign the informed consent * Limited capacity of consent on the part of the donor, if there is no legally determined guardian/authorised representative, or the latter is not present or does not agree with the inclusion * Active cancer * Pregnant women * Underage subjects of less than 18 years of age * Refusal to comply with mandatory sample collection * For invasive procedures, i.e., lumbar puncture and skin biopsy: relevant blood clotting impairment, e.g., anamnestic evidence of frequent or prolonged bleedings.
Where this trial is running
Luxembourg and 1 other locations
- Centre Hospitalier de Luxembourg (CHL), "Parkinson's Research Clinic" — Luxembourg, Luxembourg (RECRUITING)
- Clinical and Epidemiological Investigation Center (CIEC) — Luxembourg, Luxembourg (RECRUITING)
Study contacts
- Principal investigator: Rejko Rejko, Dr — Luxembourg Institute of Health
- Study coordinator: Rejko KRÜGER, Dr
- Email: rejko.krueger@uni.lu
- Phone: +352 44 11 4848
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Parkinson Disease, Parkinson's disease, longitudinal cohort, stratification, risk factors